JP2022548575A5 - - Google Patents

Info

Publication number
JP2022548575A5
JP2022548575A5 JP2022515966A JP2022515966A JP2022548575A5 JP 2022548575 A5 JP2022548575 A5 JP 2022548575A5 JP 2022515966 A JP2022515966 A JP 2022515966A JP 2022515966 A JP2022515966 A JP 2022515966A JP 2022548575 A5 JP2022548575 A5 JP 2022548575A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
ofatumumab
disease
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022515966A
Other languages
English (en)
Japanese (ja)
Other versions
JP7794735B2 (ja
JP2022548575A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/075332 external-priority patent/WO2021048280A1/en
Publication of JP2022548575A publication Critical patent/JP2022548575A/ja
Publication of JP2022548575A5 publication Critical patent/JP2022548575A5/ja
Priority to JP2025159217A priority Critical patent/JP2026016387A/ja
Application granted granted Critical
Publication of JP7794735B2 publication Critical patent/JP7794735B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022515966A 2019-09-11 2020-09-10 切替え療法によるrmsの治療 Active JP7794735B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025159217A JP2026016387A (ja) 2019-09-11 2025-09-25 切替え療法によるrmsの治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19196789.2 2019-09-11
EP19196789 2019-09-11
EP20154736.1 2020-01-30
EP20154736 2020-01-30
PCT/EP2020/075332 WO2021048280A1 (en) 2019-09-11 2020-09-10 Treatment of rms by switching therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025159217A Division JP2026016387A (ja) 2019-09-11 2025-09-25 切替え療法によるrmsの治療

Publications (3)

Publication Number Publication Date
JP2022548575A JP2022548575A (ja) 2022-11-21
JP2022548575A5 true JP2022548575A5 (cg-RX-API-DMAC7.html) 2023-09-13
JP7794735B2 JP7794735B2 (ja) 2026-01-06

Family

ID=72709332

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022515966A Active JP7794735B2 (ja) 2019-09-11 2020-09-10 切替え療法によるrmsの治療
JP2025159217A Pending JP2026016387A (ja) 2019-09-11 2025-09-25 切替え療法によるrmsの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025159217A Pending JP2026016387A (ja) 2019-09-11 2025-09-25 切替え療法によるrmsの治療

Country Status (15)

Country Link
US (1) US20220298253A1 (cg-RX-API-DMAC7.html)
EP (2) EP3864053B1 (cg-RX-API-DMAC7.html)
JP (2) JP7794735B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062025A (cg-RX-API-DMAC7.html)
CN (3) CN118436777A (cg-RX-API-DMAC7.html)
AU (1) AU2020344154A1 (cg-RX-API-DMAC7.html)
CA (1) CA3150947A1 (cg-RX-API-DMAC7.html)
DK (1) DK3864053T3 (cg-RX-API-DMAC7.html)
ES (1) ES2957112T3 (cg-RX-API-DMAC7.html)
FI (1) FI3864053T3 (cg-RX-API-DMAC7.html)
IL (1) IL290619A (cg-RX-API-DMAC7.html)
LT (1) LT3864053T (cg-RX-API-DMAC7.html)
MX (1) MX2022003010A (cg-RX-API-DMAC7.html)
SI (1) SI3864053T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4252847A3 (en) 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2021204994A1 (en) * 2020-04-09 2021-10-14 Novartis Ag Ofatumumab for treating ms while maintaining serum igg
CA3215371A1 (en) * 2021-04-13 2022-10-20 Shibeshih Mitiku BELACHEW Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome
CN117529336A (zh) * 2021-04-14 2024-02-06 诺华股份有限公司 用于治疗亚洲患者的多发性硬化症的奥法木单抗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
HK1231413A1 (zh) * 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
EP4252847A3 (en) * 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab

Similar Documents

Publication Publication Date Title
LÉmann et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial
Egan et al. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine
AU2013205648B2 (en) Combination treatment
JP2024102099A5 (cg-RX-API-DMAC7.html)
JP2022514194A5 (cg-RX-API-DMAC7.html)
JP7794735B2 (ja) 切替え療法によるrmsの治療
CN113288891A (zh) 治疗多发性硬化症的组合疗法
JP2013521303A5 (cg-RX-API-DMAC7.html)
JP2024178420A5 (cg-RX-API-DMAC7.html)
JP2020158544A5 (cg-RX-API-DMAC7.html)
JP5837877B2 (ja) 静脈内投与イブプロフェンを用いた患者の治療
JPH09504798A (ja) 早発性射精の治療におけるアルフゾシンまたはテラゾシンの使用
Zeng et al. LB0001 head-to-head comparison of TLL-018 and tofacitinib in patients with active rheumatoid arthritis: interim results from a phase IIa study
Wroe Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis
JP2023538065A5 (cg-RX-API-DMAC7.html)
JP2019178177A5 (cg-RX-API-DMAC7.html)
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
JP2013500964A (ja) 静脈内イブプロフェンを用いた重篤な病気の患者の治療
Delmendo et al. Current strategies in the treatment of multiple sclerosis
van Riel et al. Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis
HK40123216A (en) Method for treating multiple sclerosis
AU2023381309A1 (en) Method for treating multiple sclerosis
TW202535928A (zh) 治療化膿性汗腺炎之方法
Etemadifar et al. Fingolimod versus high dose interferon beta-1a in multiple sclerosis: a randomized clinical trial
EP0966286B1 (en) Attenuation of opioid tolerance by inhibiting inducible nitric oxide synthase pathways in the treatment of pain